Managing severe community-acquired pneumonia due to community methicillin-resistant staphylococcus aureus (MRSA)

Current Infectious Disease Reports

Volumn 14, Issue 3, 2012, Pages 330-338

  Kwong, Jason C ^a   Chua, Kyra ^a   Charles, Patrick G P ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

CAP; Ceftaroline; Community acquired MRSA; Community acquired pneumonia; Linezolid; Methicillin resistant Staphylococcus aureus; MRSA; Necrotizing pneumonia; NORSA; Panton Valentine Leukocidin; PVL; Staphylococcus aureus pneumonia; Vancomycin

Indexed keywords

ALPHA HEMOLYSIN; CARBAPENEM DERIVATIVE; CEFTAROLINE; CEFTOBIPROLE; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; FUSIDIC ACID; IMMUNOGLOBULIN G; LINEZOLID; PANTON VALENTINE LEUKOCIDIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BONE MARROW SUPPRESSION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG ERUPTION; DRUG POTENTIATION; DRUG USE; FEVER; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEMOPTYSIS; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HYPOTENSION; KIDNEY DISEASE; LACTIC ACIDOSIS; LIVER DISEASE; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEUROPATHY; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; QT PROLONGATION; SCREENING TEST; SEROTONIN SYNDROME; SKIN MANIFESTATION; TENDINITIS; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84865617995     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0254-8     Document Type: Article

References (96)

1. Charles PG, Whitby M, Fuller AJ, et al. The etiology of communityacquired pneumonia in Australia: Why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis. 2008;46 (10):1513-21. (Pubitemid 351706731)
2. File TM. Community-Acquired pneumonia. Lancet. 2003;362 (9400):1991-2001. 3. 9.
3. Hidron AI, Low CE, Honig EG, Blumberg HM. Emergence of community-Acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis. 2009;9(6):384-92. This article provides an excellent review of pneumonia due to the USA300 strain of community MRSA, including important differences between nosocomial MRSA and community MRSA pneumonia.
4. Cilloniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-Acquired pneumonia and its relation to severity. Thorax. 2011;66(4):340-6.
5. Chua KY, Seemann T, Harrison PF, et al. The dominant Australian community-Acquired methicillin-resistant Staphylococcus aureus clone ST93-IV [2B] is highly virulent and genetically distinct. PLoS One. 2011;6(10):e25887.
6. Li M, Cheung GY, Hu J, et al. Comparative analysis of virulence and toxin expression of global community-Associated methicillinresistant Staphylococcus aureus strains. J Infect Dis. 2010;202 (12):1866-76.
7. Chua K, Laurent F, Coombs G, et al. Antimicrobial resistance: Not community-Associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to communityMRSA -its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis. 2011;52(1):99-114. This article provides a clinically-based review including the global epidemiology of community MRSA.
8. Francis JS, Doherty MC, Lopatin U, et al. Severe communityonset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40(1):100-7. (Pubitemid 40053465)
9. Geng W, Yang Y, Wu D, et al. Community-Acquired, methicillinresistant Staphylococcus aureus isolated from children with community-onset pneumonia in China. Pediatr Pulmonol. 2010;45 (4):387-94.
10. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359(9308):753-9. (Pubitemid 34215075)
11. Hageman JC, Uyeki TM, Francis JS, et al. Severe communityacquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12(6):894-9. (Pubitemid 43848409)
12. Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-Acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest. 2010;138(1):130-6. This article details the clinical presentation of 15 patients with community MRSA at a single centre. 14 patients had USA300 (or a closely-related strain) and the other USA400.
13. Peleg AY, Munckhof WJ. Fatal necrotising pneumonia due to community-Acquired methicillin-resistant Staphylococcus aureus (MRSA). Med J Aust. 2004;181(4):228-9. (Pubitemid 39172946)
14. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-Acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis. 2007;45(3):315-21. (Pubitemid 47101027)
15. 1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection. PLoS One. 2010;5(1):e8705
16. Deleo FR, Otto M, Kreiswirth BN, Chambers HF. Communityassociated meticillin-resistant Staphylococcus aureus. Lancet. 2010;375(9725):1557-68. This article provides an excellent overview of community MRSA.
17. Boyle-Vavra S, Daum RS. Community-Acquired methicillinresistant Staphylococcus aureus: The role of Panton-Valentine leukocidin. Lab Invest. 2007;87(1):3-9. (Pubitemid 44973648)
18. Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science. 2007;315(5815):1130-3. (Pubitemid 46328024)
19. Loffler B, Hussain M, Grundmeier M, et al. Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog. 2010;6(1):e1000715.
20. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-Associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis. 2006;194(12):1761-70. (Pubitemid 44902009)
21. Diep BA, Chan L, Tattevin P, et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidininduced lung inflammation and injury. Proc Natl Acad Sci U S A. 2010;107(12):5587-92.
22. Bubeck Wardenburg J, Bae T, Otto M, et al. Poring over pores: Alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med. 2007;13(12):1405-6. (Pubitemid 350224232)
23. Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-Acquired meticillinresistant Staphylococcus aureus. Lancet. 2006;367(9512):731-9. (Pubitemid 43326291)
24. Montgomery CP, Boyle-Vavra S, Daum RS. The arginine catabolic mobile element is not associated with enhanced virulence in experimental invasive disease caused by the community-Associated methicillin-resistant Staphylococcus aureus USA300 genetic background. Infect Immun. 2009;77(7):2650-6.
25. Diep BA, Stone GG, Basuino L, et al. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: Convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis. 2008;197 (11):1523-30. (Pubitemid 351706482)
26. Bodi M, Ardanuy C, Rello J. Impact of Gram-positive resistance on outcome of nosocomial pneumonia. Crit Care Med. 2001;29(4 Suppl):N82-6.
27. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis. 1999;29(5):1171-7. (Pubitemid 30265635)
28. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, et al. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011;11(3):208-22. This article details some of the finer points in management of Staphylococcus aureus bacteremia.
29. Khatib R, Johnson LB, Sharma M, et al. Persistent Staphylococcus aureus bacteremia: Incidence and outcome trends over time. Scand J Infect Dis. 2009;41(1):4-9.
30. Siegman-Igra Y, Reich P, Orni-Wasserlauf R, et al. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis. 2005;37(8):572-8.
31. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-careassociated pneumonia: Specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006;130(4):947-55. (Pubitemid 44583720)
32. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996;38(5):865-9. (Pubitemid 26413723)
33. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993;37(2):281-6. (Pubitemid 23046569)
34. Harigaya Y, Bulitta JB, Forrest A, et al. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin- resistant Staphylococcus aureus (MRSA): Implications for dosing in MRSA pneumonia. Antimicrob Agents Chemother. 2009;53(9):3894-901.
35. Welte T, Pletz MW. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: Current and future options. Int J Antimicrob Agents. 2010;36 (5):391-400.
36. Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: A proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006;50 (4):1599-602.
37. Howden BP. Linezolid. In: Grayson ML, Crowe SM, McCarthy JS et al., editors. Kucer's the use of antibiotics. 6th ed. London: Hodder Education/ASM Press; 2010. p. 895-919.
38. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32(3):402-12. (Pubitemid 32173626)
39. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25(3):980-92. (Pubitemid 36459702)
40. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124(5):1789-97. (Pubitemid 37433574)
41. Powers JH, Ross DB, Lin D, Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: The subtleties of subgroup analyses. Chest. 2004;126 (1):314-5. author reply 5-6.
42. Kalil AC, Puumala SE, Stoner J. Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest. 2004;125(6):2370-1. (Pubitemid 38788219)
43. Howden BP, Charles PG, Johnson PD, et al. Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: Aetter drug or reduced vancomycin susceptibility? Antimicrob Agents Chemother. 2005;49(11):4816. author reply -7. 44. 9.
44. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study. Clin Infect Dis. 2012;54 (5):621-9. This was a well-designed study of vancomycin vs linezolid in treatment of nosocomial pneumonia.
45. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55.
46. Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycinintermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99-139.
47. Kalil AC, Murthy MH, Hermsen ED, et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-Analysis. Crit Care Med. 2010;38(9):1802-8.
48. Lim WS, Baudouin SV, George RC et al. BTS guidelines for the management of community acquired pneumonia in adults: Update 2009. Thorax. 2009;64 Suppl 3:iii55.
49. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-Acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72. (Pubitemid 46290553)
50. Nathwani D, Morgan M, Masterton RG, et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61(5):976-94. (Pubitemid 351545546)
51. Barton M, Hawkes M, Moore D, et al. Guidelines for the prevention and management of community-Acquired methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners. Canadian Journal of Infectious Diseases & Medical Microbiology. 2006;17(Supplement C):4C-24C.
52. Respiratory Infections Expert Group. Respiratory tract infections: Pneumonia. Antibiotic Expert Group. Therapeutic Guidelines: Antibiotic. Version 14. Melbourne: Therapeutic Guidelines Limited; 2010.
53. Bayer AS, Morrison JO. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984;26(2):220-3. (Pubitemid 14050231)
54. Foldes M, Munro R, Sorrell TC, et al. In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1983;11(1):21-6. (Pubitemid 13174519)
55. Jung YJ, Koh Y, Hong SB, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med. 2010;38 (1):175-80.
56. Saginur R, Stdenis M, Ferris W, et al. Multiple combination bactericidal testing of staphylococcal biofilms from implantassociated infections. Antimicrob Agents Chemother. 2006;50 (1):55-61. (Pubitemid 43042902)
57. Street AC, Korman TM. Rifampicin. In: Grayson ML, Crowe SM, McCarthy JS et al., editors. Kucer's the use of antibiotics. 6th ed. London: Hodder Education/ASM Press; 2010. p. 1587-626.
58. McDougal LK, Fosheim GE, Nicholson A, et al. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob Agents Chemother. 2010;54(9):3804-11.
59. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2002;21(6):530-4. (Pubitemid 34625834)
60. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-Acquired methicillin-resistant Staphylococcus aureus: Importance of treatment with antimicrobials inhibiting exotoxin production. Chest. 2005;128(4):2732-8. (Pubitemid 41507634)
61. Ho JL, Klempner MS. In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus. Diagn Microbiol Infect Dis. 1986;4(2):133-8. (Pubitemid 16036592)
62. Booker BM, Stahl L, Smith PF. In vitro antagonism with the combination of vancomycin and clindamycin against Staphylococcus aureus. Journal of Applied Research. 2004;4:385-95. (Pubitemid 39299383)
63. Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother. 2003;47(6):1902-6. (Pubitemid 36637812)
64. Nguyen HM, Graber CJ. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: Is combination therapy the answer? J Antimicrob Chemother. 2010;65(1):24-36. This article outlines the potential of combination therapy for severe MRSA infections.
65. Tarasi A, Cassone M, Monaco M, et al. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-Associated infections unresponsive to glycopeptide therapy. J Chemother. 2003;15(3):239-43. (Pubitemid 36819311)
66. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2009;49(7):1072-9.
67. Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(1):418-20. (Pubitemid 36070400)
68. Drancourt M, Stein A, Argenson JN, et al. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother. 1993;37(6):1214-8. (Pubitemid 23166716)
69. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117 (5):390-8.
70. Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-Trimethoprim against intracellular phagocytized MRSA. J Infect Chemother. 2007;13 (3):141-6. (Pubitemid 47012505)
71. Kimura A, Mochizuki T, Nishizawa K, et al. Trimethoprimsulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients. J Trauma. 1998;45(2):383-7. (Pubitemid 28399736)
72. Jacqueline C, Caillon J, Grossi O, et al. In vitro and in vivo assessment of linezolid combined with ertapenem: A highly synergistic combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(7):2547-9. (Pubitemid 43993202)
73. Jacqueline C, Navas D, Batard E, et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49 (1):45-51. (Pubitemid 40065771)
74. Linezolid Alone or CombinedWith Carbapenem Against Methicillinresistant Staphylococcus Aureus (MRSA) in Ventilator-Associated Pneumonia. US National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT01356472. December 2011.
75. Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother. 2003;51 (4):857-64. (Pubitemid 36503419)
76. Jorgenson MR, Depestel DD, Carver PL. Ceftaroline Fosamil: A Novel Broad-Spectrum Cephalosporin with Activity Against Methicillin-Resistant Staphylococcus aureus. Ann Pharmacother. 2011;45(11):1384-98.
77. Germel C, Haag A, Soderquist B. In vitro activity of beta-lactam antibiotics to community-Associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Eur J Clin Microbiol Infect Dis. 2011.
78. Kollef MH. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc. 2009;11(4):282-6.
79. Nicasio AM, Kuti JL, Nicolau DP. Telavancin. In: Grayson ML, Crowe SM,McCarthy JS et al., editors. Kucer's the use of antibiotics. 6th ed. London: Hodder Education/ASM Press; 2010. p. 654-60.
80. Nabuurs-Franssen MH, Mouton JW. Tigecycline. In: Grayson ML, Crowe SM, McCarthy JS et al., editors. Kucer's the use of antibiotics. 6th ed. London: Hodder Education/ASM Press; 2010. p. 881-92.
81. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis. 2005;191(12):2149-52. (Pubitemid 40800587)
82. Koplowicz YB, Schwartz BS, Guglielmo BJ. Development of daptomycin-susceptible, methicillin-resistant Staphylococcus aureus pneumonia during high-dose daptomycin therapy. Clin Infect Dis. 2009;49(8):1286-7.
83. Noah MA, Dawrant M, Faulkner GM, et al. Panton-Valentine leukocidin expressing Staphylococcus aureus pneumonia managed with extracorporeal membrane oxygenation: Experience and outcome. Crit Care Med. 2010;38(11):2250-3.
84. Gauduchon V, Cozon G, Vandenesch F, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis. 2004;189(2):346-53. (Pubitemid 38147260)
85. Hampson FG, Hancock SW, Primhak RA. Disseminated sepsis due to a Panton-Valentine leukocidin producing strain of community acquired meticillin resistant Staphylococcus aureus and use of intravenous immunoglobulin therapy. Arch Dis Child. 2006;91(2):201. (Pubitemid 43362533)
86. Rouzic N, Janvier F, Libert N, et al. Prompt and successful toxintargeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton-Valentine leukocidin genes. J Clin Microbiol. 2010;48(5):1952-5.
87. Dumitrescu O, Boisset S, Badiou C, et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother. 2007;51(4):1515-9. (Pubitemid 46586841)
88. Ohlsen K, Ziebuhr W, Koller KP, et al. Effects of subinhibitory concentrations of antibiotics on alpha-Toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 1998;42(11):2817-23. (Pubitemid 28501209)
89. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-Associated exotoxin genes in methicillinsensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis. 2007;195(2):202-11. (Pubitemid 46080052)
90. Dumitrescu O, Choudhury P, Boisset S, et al. Beta-lactams interfering with PBP1 induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(7):3261-71.
91. Guidance on the diagnosis and management of PVL-Associated Staphylococcus aureus infections (PVL-SA) in England. 2nd ed: Health Protection Agency; 2008.
92. Napolitano LM, Brunsvold ME, Reddy RC, Hyzy RC. Community-Acquired methicillin-resistant Staphylococcus aureus pneumonia and ARDS: 1-year follow-up. Chest. 2009;136 (5):1407-12.
93. Peleg AY, Munckhof WJ, Kleinschmidt SL, et al. Life-Threatening community-Acquired methicillin-resistant Staphylococcus aureus infection in Australia. Eur J Clin Microbiol Infect Dis. 2005;24 (6):384-7. (Pubitemid 40933912)
94. von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001;344(1):11-6. (Pubitemid 32064839)
95. Sandri AM, Dalarosa MG, RuscheldeAlcantara L, et al. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp Epidemiol. 2006;27 (2):185-7. (Pubitemid 43384766)
96. Zafar U, Johnson LB, Hanna M, et al. Prevalence of nasal colonization among patients with community-Associated methicillinresistant Staphylococcus aureus infection and their household contacts. Infect Control Hosp Epidemiol. 2007;28(8):966-9. (Pubitemid 47218277)